CAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will ...
FL-501 is a potential best-in-class monoclonal antibody in preclinical development that targets growth differentiation factor-15 (GDF-15), a cytokine that is produced at elevated levels in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results